Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.

Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer's disease (AD).

Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory (NPI-4-A/A) derived from the Neuropsychiatric Inventory. Secondary measures included the Cohen-Mansfield Agitation Inventory, Cornell Scale for Depression in Dementia, Frontal Systems Behavior Inventory (FrSBe), and Alzheimer's Disease Assessment Scale-Cognitive.

Influence of sub-syndromal symptoms after remission from manic or mixed episodes.

Background: Sub-syndromal symptoms in bipolar disorder impair functioning and diminish quality of life.

Aims: To examine factors associated with time spent with sub-syndromal symptoms and to characterise how these symptoms influence outcomes.

Method: In a double-blind randomised maintenance trial, patients received either olanzapine or lithium monotherapy for 1 year.